AI_collection_hero-7cd68d878c8b910a5114df2f4293f251 (1)

Three Selvedge Venture portfolio companies were featured in the April issue of Nature

Nature has published their April 2022 Biopharma Dealmakers collection on the Advances in Artificial Intelligence-Driven Drug Development presenting companies “harnessing the power of artificial intelligence for the development of cutting-edge tools and novel approaches to accelerate drug discovery and research”. 

We are very excited to have three Selvedge Venture Life Sciences AI companies featured in this collection! Click the links below to view the individual articles:

BIOS Health: Using data-driven insigths from the nrevous system to build neural digital therapies

Exogene Ltd: How artificial intelligence is enabling T cell receptor screening for cell therapy discovery

Multiomic Health Limited: Leveraging deep omics data to tackle a global health challenge with precision


On a journey to drastically speed up cell therapy manufacturing, Kytopen lands $30M Series A

Spun out of an MIT lab, sitting in an office space above a Cambridge tapas restaurant from world-renowned chef Ken Oringer is a biotech focused on drastically reducing the amount of time it takes to make cell therapies. And Tuesday, the company co-founded by Paulo Garcia and Cullen Buie said it raised $30 million in Series A funding.

The funding will go toward commercializing its system for accelerating engineered cell therapy production, known as Flowfect Tx. The round also will allow the company to move toward treating its first human with the technology, which it says can engineer simple non-viral manufacturing of cell therapies in just a few days as opposed to weeks.

The fundraising round was led by Northpond Ventures, which said that Kytopen stood out because of its platform-driven approach that broadly addresses the needs of therapeutics. Current investors The Engine, Horizon Ventures, and Mass Ventures all contributed to the round, as well as Aldevron co-founders Michael Chambers and John Ballantyne and Alexandria Venture Investments.


London-based health startup snaps up £2M to turbocharge diagnostics development with clinically validated home testing

The complexity of health and disease cannot be captured by a singular diagnostic test and therefore can’t be expected to deliver true impact. Attempting to create a paradigm shift in diagnostics development by making them 10x more effective, faster and impactful is London-based early-stage biotech company Sanome.

The health startup has raised £2 million as its first round of funding from a number of leading UK and European health tech specialist investors. The round was led by Heal Capital, with participation from Crista Galli Ventures, Selvedge Ventures, o2h Ventures, Meltwind and a number of high-profile angels, including David Cleevely and Pam Garside.

Screen Shot 2021-06-24 at 16.50.06

WSJ features Ochre Bio: “Biotech Startup Ochre Bio Lands Seed Financing to Combat Liver Diseases”

Brian Gormley ⁦of The Wall Street Journal has featured Ochre Bio and their novel approach to tackling chronic liver disease (a top ten cause of death globally).

“We’re starting with a focus on improving outcomes for transplant patients, and are making exciting progress scientifically here in Oxford. With great investors onboard, a wonderful team coming together, and an international network of transplant / clinical partners – we are well on our way to developing life-saving medicines for one of the toughest healthcare challenges of our time” said Ochre Bio.

Screen Shot 2021-06-24 at 16.36.22

CogX Shortlists BIOS in their AI awards for Best Innovation in Pharma

We are thrilled to announce that BIOS was shortlisted for the “Best Innovation in Pharma” in this year’s CogX Awards.

The CogX Awards are the most exciting celebration of innovation and transformational opportunities in the world – a time to give the companies and individuals making a difference a platform.

This year, award categories are spread across six themes: Recognising Leadership, Best AI Product, Best Innovation, Outstanding Achievements & Research Contributions, Best Climate Innovation and Global Goals – with more than 60 individual categories covering verticals from AI to Global Leadership, Financial Services to Climate Change, and from GenZ to Covid-19 Response.